In the 2009 European Guidelines on the diagnosis and treatment of pulmonary hypertension (PH), one section covers aspects of pathophysiology, diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The practical implementation of the guidelines for this disease is of crucial importance, because CTEPH is a subset of PH which can potentially be cured by pulmonary endarterectomy (PEA). Nowadays, CTEPH is commonly underdiagnosed and not properly managed. Any patient with unexplained PH should be evaluated for the presence of CTEPH, and a ventilation/perfusion (V/Q) lung scan is recommended as screening method of choice. If the V/Q scan or CT angiography reveals signs of CTEPH, the patient should be referred to a specialized center with expertise in the medical and surgical management of this disease. Every case has to be reviewed by an experienced PEA surgeon for the assessment of operability. In this updated recommendation, important contents of the European guidelines were commented, and more recent information regarding diagnosis and treatment was added.
für Kardiologie, DGK), the German Society of Respiratory Medicine (Deutsche Gesellschaft für Pneumologie, DGP) and the German Society of Pediatric Cardiology (Deutsche Gesellschaft für pädi-atrische Kardiologie, DGPK). This conference addressed practical issues surrounding the implementation of the European Guidelines for diagnosis and treatment of pulmonary hypertension in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The authors were members of this working group. The corresponding articles were initially published in the Deutsche Medizinische Wochenschrift, and the information was now updated in October 2011. Below, the corresponding sections of the European Guidelines are summarized [1] [2] [3] whereby comments and additions appear in italics. The information on class of recommendation and level of evidence correspond to the tables listed in the preamble of this supplement.
Definition and pathogenesis
CTEPH is defined as pre-capillary PH as assessed by right heart catheterization (mean PAP ≥25 mmHg, PCWP ≤15 mmHg) in the presence of multiple chronic/organized occlusive thrombi/emboli in the elastic pulmonary arteries (main, lobar, segmental, subsegmental) after at least three months of effective anticoagulation [1, 2] . CTEPH is thought to result from isolated or recurrent pulmonary thromboembolism and represents one of the most prevalent forms of PH. Although most patients with pulmonary embolism (PE) do not develop CTEPH [4] , the disease appears to be more prevalent than previously assumed [5] . Two prospective cohort studies demonstrated a cumulative incidence of symptomatic CTEPH of 3.8% [6] and 1.5% [7] after acute PE, respectively. Nevertheless, it is almost impossible to determine the overall prevalence of CTEPH since not all of these patients have a history of acute PE. In fact, CTEPH is frequently found in patients without any previous clinical episode of acute PE or deep venous thrombosis (up to 50% in different series) [8] .
The pathogenesis of CTEPH is complex and has not been fully understood [8] . The most important pathobiological process is nonresolution of acute embolic masses which later undergo fibrosis, thus leading to mechanical obstruction of pulmonary arteries [1, 2] . Unlike in acute PE, there is no linear correlation between a compromised hemodynamic state and the mechanical obstruction of pulmonary arteries. Pulmonary thromboembolism or in situ thrombosis may be initiated or aggravated by abnormalities in either the clotting cascade, endothelial cells, or platelets, all of which interact in the coagulation process [5] . Thus, coagulation and fibrinolytic disorders are thought to contribute to the development of the disease. In addition, other factors such as abnormal fibrinogen and immunological, inflammatory, or infectious mechanisms trigger pathological remodeling of major and small pulmonary vessels as a response to misguided thrombus resolution (Fig. 1) .
Platelet abnormalities and biochemical features of a procoagulant environment within the pulmonary vasculature support a potential role for thrombus formation in initiating the disease in some patients. In most cases, it remains unclear whether thrombosis and platelet dysfunction are a cause or consequence of the disease. Inflammatory infiltrates are commonly detected in the pulmonary endarterectomy (PEA) specimens [1, 2] .
While acute PE may be clinically silent [9] , there is accumulating evidence that CTEPH may also develop in the absence of previous PE [8] . In these cases, the disease is probably initiated by thrombotic or inflammatory lesions in the pulmonary vasculature. Fig. 1 . Current hypothesis for the pathobiology of CTEPH (according to [5, 8] .)
Once vessel obliteration is sufficient to cause increases in the PAP, a process of pulmonary vascular remodeling is started which selfperpetuates the progression of PH, even in the absence of further thromboembolic events [1, 2] .
Pathological lesions are characterized by organized thrombi tightly attached to the pulmonary arterial medial layer in the elastic pulmonary arteries, replacing the normal intima. These may completely occlude the lumen or form different grades of stenoses, webs, and bands [4] . Interestingly, in the non-occluded areas, a pulmonary arteriopathy indistinguishable from that of PAH (including plexiform lesions) can develop [10] . Obstructive lesions observed in the distal pulmonary arteries of non-obstructed areas may be related to a variety of factors, such as shear stress, pressure, inflammation, and the release of cytokines and vasculopathic mediators. Collateral vessels from the systemic circulation (from bronchial, costal, diaphragmatic and coronary arteries) can grow to reperfuse at least partially the areas distal to complete obstructions [1, 2] .
Thrombophilia and CTEPH
Traditional risk factors for venous thromboembolism (VTE) include antithrombin deficiency, protein C deficiency, protein S deficiency, factor V Leiden, plasminogen deficiency, and anticardiolipin antibodies [9] . However, in 147 consecutive patients with CTEPH, the prevalence of hereditary thrombotic risk factors (antithrombin mutations, protein S, protein C, factor II or factor V Leiden) was not increased when compared to 99 consecutive patients with IPAH or to 100 control patients (Table 1 ) [11] .
Thrombophilia studies have shown that lupus anticoagulant may be found in ∼10% of CTEPH patients, and 20% carry antiphospholipid antibodies, lupus anticoagulant, or both [12] . A recent study has demonstrated that the plasma level of factor VIII, a protein associated with both primary and recurrent VTE, is elevated in 39% of patients with CTEPH [12] . No abnormalities of fibrinolysis have been identified [1, 2] . Blood groups type A, B, and AB were found to be significantly more common in patients with CTEPH compared to patients with PAH (88% vs. 56%) [13] . Plasma lipoprotein levels (a) (Lp(a)), a subgroup of the low density lipoprotein with high atherogenic potency, were significantly higher in patients with CTEPH than in patients with PAH and control subjects, indicating an overlap of venous and arterial thrombotic risk factors [14] .
Factors that are associated with the development of CTEPH
In addition to thrombophilia, certain conditions are associated with an increased risk for CTEPH [1, 2] , including previous splenectomy, the presence of a ventriculo-atrial (VA) shunt for the treatment of hydrocephalus, myeloproliferative disorders, infected intravenous lines, and chronic inflammatory disorders, such as osteomyelitis and inflammatory bowel diseases [14] [15] [16] . While these associated conditions have a negative impact on survival [17] , the mechanism(s) linking these conditions to CTEPH have not been fully explored, but chronic inflammation or chronic blood stream infection may play a critical role [13] .
Diagnostic procedures
Any patient with unexplained PH should be evaluated for the presence of CTEPH. Suspicion should be high when the patient presents with a history of previous venous thromboembolism. Survivors of acute PE should be followed after the acute episode to detect signs and symptoms of CTEPH. Patients with acute PE showing signs of PH or RV dysfunction at any time during their hospital stay should receive a follow-up echocardiography after discharge (usually after 3-6 months) to determine whether or not PH has resolved [1, 2] .
In patients with unexplained PH, a ventilation/perfusion lung scan (comment: planar images on at least 6 views + SPECT) is recommended to exclude CTEPH [18, 19] , since the sensitivity is greater than that of computed tomography [20] . While a normal ventilation/perfusion lung scan rules out CTEPH, unmatched perfusion defects can also occur in other conditions (see Table 2 ).
Multidetector-row CT angiography is indicated when the ventilation/perfusion lung scan is indeterminate or reveals perfusion defects (see specific recommendations of the working group). Even in the era of modern multirow CT scanners, there is not yet enough evidence to suggest that a normal CT angiography excludes the presence of operable CTEPH [1, 2] . Nevertheless, CT angiography may show complete obstruction, stenoses, strictures, or intimal irregularities [21, 22] . Parenchymal lesions and hypertrophic bronchial collaterals are visualized.
Once perfusion/ventilation scanning and/or CT angiogram show signs compatible with CTEPH, the patient should be referred to a center with expertise in the medical and surgical management of these patients [1, 2] . To determine the appropriate therapeutic strategy, invasive tools including right heart catheterization and traditional pulmonary angiography are usually required [4] . Coronary angiography is indicated in candidates for PEA and risk factors for coronary heart disease. In order to minimize risks and repeated procedures, these investigations should be performed at an expert center rather than at the referring hospitals [23] . The final diagnosis of CTEPH is based on the presence of precapillary PH as assessed by right heart catheterization (mean PAP ≥25 mmHg, PCWP 15 mmHg, PVR >2 Wood units) in patients with mutiple chronic/organized occlusive thrombi/emboli in the elastic pulmonary arteries (main, lobar, segmental, subsegmental) [1, 2] . Furthermore, the decision about potential PEA is made by reviewing the patient history and functional class, ventilation/perfusion lung scan, selective pulmonary angiography, CT angiography, and right heart catheterization ( Fig. 2, Table 3 ). Blood group and thrombophilia screening including AT III, lupus anticoagulant, and anti-cardiolipin antibodies should be performed.
Comments:
The diagnostic tools to assess the severity of CTEPH are the same as for PAH. There is, however, less available data for patients with CTEPH than for patients with PAH. Other imaging procedures such as MRI [24] and angioscopy [25] are not mentioned in the ESC/ERS guidelines but may be applied depending on the experience of the respective center.
In order to determine the therapeutic strategy for patients with CTEPH, one study suggested that vasoreactivity testing may be used within the scope of right heart catheterization [26] , although the consequences of such testing remain unclear. Analysis of the pressure decay curves in right heart catheterization during pulmonary arterial occlusion can help identify a distal component of vasculopathy [27] . Fig. 2 ).
Treatment of CTEPH
Patients with CTEPH should receive life-long anticoagulation, usually with vitamin K antagonists adjusted to a target INR between 2.0 and 3.0.
The decision on how to treat patients with CTEPH should be made at an expert center based upon interdisciplinary discussion among internists, radiologists, and expert surgeons. Pulmonary endarterectomy (PEA) is the treatment of choice for patients with CTEPH as it is a potentially curative treatment option. As a rule, a patient should not be considered inoperable as long as the case has not been reviewed by an experienced PEA surgeon. Detailed pre-operative patient evaluation and selection, surgical technique and experience, and meticulous post-operative management are essential prerequisites for success after this intervention [21] . The selection of patients for surgery depends on the extent and location of the organized thrombi in relation to the degree of PH, and taking into consideration age and co-morbidities. Proximal organized thrombi represent the ideal indication, while more distal obstructions may complicate or prevent a successful procedure. After an effective intervention, a dramatic drop of pulmonary vascular resistance can be expected with a near normalization of pulmonary hemodynamics. A center can be considered to have sufficient expertise in this field if it performs at least 20 PEA operations per year with a mortality rate <10% [1, 2] .
Specific PAH drug therapy has thus far not proven effective in CTEPH. However, targeted treatments may be considered in selected patients with CTEPH, mainly for three different scenarios: (i) if patients are not considered candidates for surgery; (ii) if pre-operative treatment is deemed appropriate to improve hemodynamics, and (iii) if patients present with symptomatic residual/recurrent PH after PEA or develop PH once more after PEA had been performed [1, 2] . Several uncontrolled clinical studies suggest that prostanoids, endothelin receptor antagonists, and phosphodiesterase type-5 in- Table 4 Recommendations of the ESC/ERS guidelines for CTEPH [1, 2] .
Recommendation
Class of recommendation
Level of evidence
The diagnosis of CTEPH is based on the presence of pre-capillary PH (mean PAP ≥25 mmHg, PCWP ≤15 mmHg, PVR >2 Wood units) in patients with multiple chronic/organized occlusive thrombi/emboli in the elastic pulmonary arteries (main, lobar, segmental, subsegmental), persisting after effective anticoagulation over a minimum period of three months.
I C
In patients with CTEPH, lifelong anticoagulation is indicated.
Surgical pulmonary endarterectomy (PEA) is the recommended treatment for patients with CTEPH.
Once perfusion scanning and/or CT angiography shows signs compatible with CTEPH, the patient should be referred to a center with expertise in surgical pulmonary endarterectomy.
IIa C
The selection of patients for surgery should be based on the extent and location of the organized thrombi, on the degree of PH, and on the presence of co-morbidities.
IIa C PAH-specific drug therapy may be indicated in selected CTEPH patients such as patients who are not candidates for surgery or patients with residual PH after pulmonary endarterectomy.
IIb C hibitors may exert hemodynamic and clinical benefits in patients with CTEPH, regardless of whether these patients were considered operable or inoperable [28] [29] [30] [31] [32] [33] [34] [35] . The only randomized, placebocontrolled clinical trial that has so far addressed the safety and efficacy of targeted medical treatment was the BENEFIT study (Bosentan Effects in inoperable Forms of chronic thromboembolic pulmonary hypertension), which investigated the effects of bosentan in patients with inoperable CTEPH for a 16-week period [36] . This study revealed a significant drop in PVR in the bosentan group but no change in the 6-minute walking test, WHO functional class, or time to clinical worsening [1, 2] . Given these limited data, further studies are necessary to obtain reliable long-term data on the effect of medical therapies in patients with CTEPH, and these patients should be treated within clinical trials whenever possible. For the present time, no medical therapy has been approved for CTEPH in Europe or the USA. Bilateral lung transplantation is an option for advanced cases that are not suited to PEA. The recommendations of the ESC/ERS guidelines for CTEPH are summarized in Table 4 [1, 2] and included in the specific recommendations of the working group.
Comment:
A PEA center is defined as an institution which performs ≥ 20 PEA surgeries per year with a mortality rate <10% [1, 2] (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) in the UK [40] . The reported rates of residual PH after PEA (mean PAP >30 mmHg) were 16.7% and 31%, respectively [39, 40] .
Recent evidence implicates that PEA may also be successfully performed in pediatric patients (reported age 8-18 years) [41] . In 
